Treatment of malignant, non-resectable, epithelial origin esophageal tumors with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy

Article

Abstract: Overexpression of epidermal growth factor receptor in esophageal cancer is associated with poor prog

Palabras claves:

Chemorariotherapy, Esophageal cancer, Humanized monoclonal, nimotuzumab

Autores:

Albuerne Y.A., Alert J., Alvarez E.S., Callejo I.P., De La Vega H.A., Gonzalez C.E.V., Gonzalez Y.S., Hernadez I.M., Lazo N.G., Luaces P.L.o., Martell J.A.n., Moreno B.P., Perez M.L., Ramos-Suzarte M., Ruiz-Garcia E.B., Soriano J.L., Tania Crombet

Fuentes:

scopus